Gray Market Peptides: So Much Hype, So Little Data The FDA scheduled a hearing on peptides and the implications could be significant for prescribers and clinics. With BPC 157, TB 500, and others under 503A review, questions around compounding, compliance, and what is FDA Compliance for Peptide Therapy and BPC 157 Holt Law Injectable Peptides: Out of the Back Alley and Into the Light? Berkley Lifesciences